Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Business Wire May 10, 2023

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

Business Wire May 9, 2023

ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023

Business Wire May 2, 2023

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Business Wire March 15, 2023

ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Business Wire March 1, 2023

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Business Wire February 28, 2023

ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023

Business Wire February 21, 2023

ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder

Business Wire February 2, 2023

ADC Therapeutics to Participate in February Investor Conferences

Business Wire February 1, 2023

ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2023

ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

Business Wire January 3, 2023

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire December 21, 2022

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

Business Wire December 19, 2022

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

PR Newswire December 12, 2022

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Business Wire November 28, 2022

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Business Wire November 8, 2022

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Business Wire November 7, 2022

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

Business Wire November 3, 2022

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

GlobeNewswire November 2, 2022

ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

Business Wire November 1, 2022